Prostate Cancer Cells Induce Osteoclastogenesis And Bone Resorption Through Rankl-Independent Interleukin-8 (Il-8) And Monocyte Chemoattractant Protein-1 (Mcp-1) Production

yi lu,zhong cai,guozhi xiao,zhi yao,judy anderson,david roodman,jian zhang

IF: 11.2

2006-01-01

Cancer Research

Abstract:Proc Amer Assoc Cancer Res, Volume 47, 2006 3972 Prostate cancer (CaP) commonly metastasizes to bone resulting in high mortality. Strategies to inhibit prostate cancer metastasis include targeting both tumor-induced osteoblastic lesions and underlined, possibly prerequisite, osteoclastic activities at the bone metastatic sites. We have previously demonstrated that blocking receptor activator of NFκB ligand (RANKL) partially prevent the establishment of CaP in bone and diminishes the progression of CaP growth in the skeleton in murine models. However, RANKL in the serum from CaP patients or from the bone marrow of tumor sites in animal models or in the cell lines used in those studies was at very low level. These findings strongly suggest that soluble factors other than RANKL may mediate the tumor-induced osteclast activity. To identify these factors we first used a human cytokine antibody array (174 cytokines) to measure cytokine protein expression in conditioned medium (CM) collected from CaP cells LNCaP and C4-2B (the derivative from LNCaP but with bone metastastatic characteristics). We found that both cells produced significantly high amount of several cytokines such as IL-8 and MCP-1, but not IL-6, IL-11, TNFα, MIP-1α, and RANTES. Furthermore, IGFBP-2 and MMP-9 were found significantly higher in C4-2B CM than LNCaP CM. (4.4-fold for IGFBP-2 and 3.1-fold for MMP-9). These results were confirmed by using ELISA. Finally, murine osteoclast precursor RAW264.7, cells or human bone marrow-derived monocytes were cultured with LNCaP CM (10%). Within 24 hours, LNCaP-CM induced multinucleated TRAP positive osteoclast formation from RAW264.7 cells while the soluble RANKL (50ng/ml) required 96 hours to form mature osteoclasts. Recombinant human IL-8 (10ng/ml), but not MCP-1 (10ng/ml), directly stimulated Raw 264.7 differentiation into mature osteoclast and bone resorption on dentin slices within 6 days of culture in the absence of RANKL. LNCaP-CM-induced osteoclast formation and bone resorption from RAW264.7 cells and human bone marrow-derived monocytes (HBMC) were dose-dependently inhibited by adding anti-IL-8 neutralizing antibody and further synergistically inhibited with addition of MCP-1 antibody in HBMC. In summary, we have identified IL-8 and MCP-1 that produced by CaP cells directly induce osteoclastogenesis and bone resorption in vitro. Together with recent report that serum IL-8 level is elevated in men with CaP and bone metastases and MCP-1 as a key mediator involved in the recruitment of monocytes/macrophages in inflamed bone, this study may provide a targeting strategy for the treatment of CaP skeletal metastasis.